NASTAD Announces 2021-2022 Board of Directors

FOR IMMEDIATE RELEASE: June 2, 2021

CONTACT: Kyle Taylor Director, Communications, NASTAD ktaylor@NASTAD.org

NASTAD Announces 2021-2022 Board of Directors

Washington, DC – Wednesday, May 26, NASTAD, a leading non-partisan non-profit association that represents public health officials who administer HIV and hepatitis programs in the U.S., announced its 2021-2022 Board of Directors. NASTAD is governed by a 23-member, elected Board charged with making policy and program decisions on behalf of the full membership.

The 2021-2022 Board of Directors includes:  

Officers (Executive Committee)

  • Marlene McNeese, Houston, Chair
  • Elizabeth Crutsinger-Perry, Washington, Chair-Elect
  • Ricardo Fernandez, Arizona, Vice Chair
  • Jeremy Turner, Indiana, Secretary-Treasurer
  • Johanne Morne, New York, Immediate Past-Chair (ex-officio, voting)
  • Stephen Lee, NASTAD Executive Director (ex-officio, non-voting)

Board Members

  • Sharon Jordan, Alabama
  • Marisa Ramos, California
  • David Kern, Chicago
  • Martin Luta, Delaware
  • Emma Spencer, Florida
  • William Lyons, Georgia
  • Randy Mayer, Iowa
  • Samuel Burgess, Louisiana
  • Colin Flynn, Maryland
  • Dawn Fukuda, Massachusetts
  • Kathryn Macomber, Michigan
  • Andrew Gans, New Mexico
  • Jacquelyn Clymore, North Carolina
  • Thomas Bertrand, Rhode Island
  • Tracey Packer, San Francisco
  • Ali Mansaray, South Carolina
  • Meredith Brantley, Tennessee

“It is my pleasure to welcome the 2021-2022 NASTAD Board of Directors,” said Stephen Lee, NASTAD Executive Director. “For the last 30 years, NASTAD has worked to lead initiatives to end the HIV and hepatitis epidemics. I am looking forward to working with the new Board of Directors to continue this work, while addressing systemic inequities and strengthening our public health infrastructure.”

###

About NASTAD Founded in 1992, NASTAD is a leading non-partisan non-profit association that represents public health officials who administer HIV and hepatitis programs in the U.S. Our singular mission is to end the intersecting epidemics of HIV, viral hepatitis, and related conditions. We do this work by strengthening governmental public health through advocacy, capacity building, and social justice.